• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    8/8/23 1:35:31 PM ET
    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DXCM alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    JNJ PUT TRADE BULLISH 09/15/23 $210.00 $34.6K 254.0K 18.9K
    DXCM CALL TRADE NEUTRAL 09/15/23 $120.00 $99.0K 2.4K 2.8K
    MRNA PUT SWEEP BEARISH 08/11/23 $98.00 $61.6K 461 1.4K
    LLY CALL SWEEP BULLISH 01/19/24 $500.00 $58.4K 1.2K 421
    VKTX PUT TRADE BEARISH 11/17/23 $16.00 $28.4K 205 97
    JAZZ PUT SWEEP BEARISH 12/20/24 $140.00 $49.5K 15 59
    NVO CALL SWEEP BEARISH 06/21/24 $185.00 $50.6K 19 54
    PFE PUT TRADE BEARISH 01/19/24 $62.50 $32.4K 60 38
    VEEV PUT TRADE BEARISH 01/17/25 $210.00 $40.4K 28 17
    RETA CALL SWEEP BEARISH 09/15/23 $140.00 $27.9K 112 15

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • Regarding JNJ (NYSE:JNJ), we observe a put option trade with bullish sentiment. It expires in 38 day(s) on September 15, 2023. Parties traded 9 contract(s) at a $210.00 strike. The total cost received by the writing party (or parties) was $34.6K, with a price of $3852.0 per contract. There were 254033 open contracts at this strike prior to today, and today 18906 contract(s) were bought and sold.

    • For DXCM (NASDAQ:DXCM), we notice a call option trade that happens to be neutral, expiring in 38 day(s) on September 15, 2023. This event was a transfer of 495 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $99.0K, with a price of $200.0 per contract. There were 2445 open contracts at this strike prior to today, and today 2886 contract(s) were bought and sold.

    • For MRNA (NASDAQ:MRNA), we notice a put option sweep that happens to be bearish, expiring in 3 day(s) on August 11, 2023. This event was a transfer of 501 contract(s) at a $98.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $61.6K, with a price of $123.0 per contract. There were 461 open contracts at this strike prior to today, and today 1433 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a call option sweep that happens to be bullish, expiring in 164 day(s) on January 19, 2024. This event was a transfer of 12 contract(s) at a $500.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $58.4K, with a price of $4870.0 per contract. There were 1281 open contracts at this strike prior to today, and today 421 contract(s) were bought and sold.

    • For VKTX (NASDAQ:VKTX), we notice a put option trade that happens to be bearish, expiring in 101 day(s) on November 17, 2023. This event was a transfer of 77 contract(s) at a $16.00 strike. The total cost received by the writing party (or parties) was $28.4K, with a price of $370.0 per contract. There were 205 open contracts at this strike prior to today, and today 97 contract(s) were bought and sold.

    • Regarding JAZZ (NASDAQ:JAZZ), we observe a put option sweep with bearish sentiment. It expires in 500 day(s) on December 20, 2024. Parties traded 28 contract(s) at a $140.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $49.5K, with a price of $1770.0 per contract. There were 15 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold.

    • For NVO (NYSE:NVO), we notice a call option sweep that happens to be bearish, expiring in 318 day(s) on June 21, 2024. This event was a transfer of 20 contract(s) at a $185.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.6K, with a price of $2530.0 per contract. There were 19 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold.

    • For PFE (NYSE:PFE), we notice a put option trade that happens to be bearish, expiring in 164 day(s) on January 19, 2024. This event was a transfer of 12 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $32.4K, with a price of $2706.0 per contract. There were 60 open contracts at this strike prior to today, and today 38 contract(s) were bought and sold.

    • Regarding VEEV (NYSE:VEEV), we observe a put option trade with bearish sentiment. It expires in 528 day(s) on January 17, 2025. Parties traded 12 contract(s) at a $210.00 strike. The total cost received by the writing party (or parties) was $40.4K, with a price of $3370.0 per contract. There were 28 open contracts at this strike prior to today, and today 17 contract(s) were bought and sold.

    • For RETA (NASDAQ:RETA), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on September 15, 2023. This event was a transfer of 10 contract(s) at a $140.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.9K, with a price of $2790.0 per contract. There were 112 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM
    $JAZZ
    $JNJ
    $LLY

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    3/10/2026$42.00Buy → Hold
    TD Cowen
    Novo Nordisk A/S
    $NVO
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    3/2/2026$41.00Buy → Neutral
    Goldman
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Jazz Pharmaceuticals plc
    $JAZZ
    2/27/2026$224.00Overweight
    Barclays
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Novo Nordisk A/S
    $NVO
    2/24/2026Buy → Hold
    Kepler
    More analyst ratings

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novo Nordisk A/S downgraded by TD Cowen with a new price target

    TD Cowen downgraded Novo Nordisk A/S from Buy to Hold and set a new price target of $42.00

    3/10/26 8:39:23 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Novo Nordisk A/S from Underweight to Equal-Weight and set a new price target of $40.00

    3/3/26 8:17:03 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S downgraded by Goldman with a new price target

    Goldman downgraded Novo Nordisk A/S from Buy to Neutral and set a new price target of $41.00

    3/2/26 8:56:43 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veeva Acquires Ostro, the Leading Brand Engagement Platform for Life Sciences

    PLEASANTON, Calif., March 10, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences that gives patients and doctors immediate, compliant answers through an easy-to-use AI-driven chat experience. Ostro-powered brand websites allow customers to easily ask questions and receive approved information, resources, and next steps in real-time. Leveraging this rich engagement data, Ostro also generates deep insights brands use to improve reach and engagement.Ostro utilizes a combination of conversa

    3/10/26 11:45:00 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    AOP Health Standardizes on Veeva Industry Cloud for Life Sciences Across All Business Areas

    International biopharma specializing in rare diseases and critical care connects R&D, quality, commercial, and data on the Veeva Vault Platform to accelerate innovationPLEASANTON, Calif. and VIENNA, March 10, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that AOP Health, an international leader in integrated therapies for rare diseases and critical care, is standardizing on applications across the Veeva Vault Platform to drive faster global growth. By connecting clinical research, development, quality, and commercialization on Veeva Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud, AOP Health can streamline operations, eliminate silos, and accelerate delive

    3/10/26 9:01:00 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

    Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig (PF-07275315) was well-tolerated with a favorable safety profile Tilrekimig has the potential to be a first-in-class, once-monthly trispecific antibody targeting interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP) for multiple chronic Type 2 (Th2) inflammatory conditions including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD) Based on encouraging results, Pfizer plans to accelerate tilrekimig to Phase 3 development, with a pi

    3/9/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    SEC Filings

    View All

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/9/26 7:53:38 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Eli Lilly and Company

    PRE 14A - ELI LILLY & Co (0000059478) (Filer)

    3/6/26 4:35:56 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

    3/5/26 1:58:46 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Viking Therapeutics Inc.

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    3/10/26 6:20:39 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    3/10/26 4:01:57 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Executive Chair Sayer Kevin R was granted 32,749 shares and covered exercise/tax liability with 32,498 shares, increasing direct ownership by 0.06% to 409,241 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    3/10/26 4:02:03 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Dexcom Appoints Rick Osterloh to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und

    2/26/26 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Financials

    Live finance-specific insights

    View All

    Veeva Acquires Ostro, the Leading Brand Engagement Platform for Life Sciences

    PLEASANTON, Calif., March 10, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences that gives patients and doctors immediate, compliant answers through an easy-to-use AI-driven chat experience. Ostro-powered brand websites allow customers to easily ask questions and receive approved information, resources, and next steps in real-time. Leveraging this rich engagement data, Ostro also generates deep insights brands use to improve reach and engagement.Ostro utilizes a combination of conversa

    3/10/26 11:45:00 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Veeva Announces Fourth Quarter and Fiscal Year 2026 Results

    Fiscal Year 2026 Total Revenues of $3,195.3M, up 16% Year Over YearQ4 Total Revenues of $836.0M, up 16% Year Over YearFiscal Year 2026 Subscription Revenues of $2,684.2M, up 17% Year Over YearQ4 Subscription Revenues of $707.7M, up 16% Year Over YearPLEASANTON, Calif., March 4, 2026 /PRNewswire/ -- Veeva Systems Inc. (NYSE:VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2026. "The agentic transformation underway represents a substantial opportunity for Ve

    3/4/26 4:05:00 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of

    3/2/26 4:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DXCM
    $JAZZ
    $JNJ
    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/12/24 5:54:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/4/24 1:54:45 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care